GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer

Journal article

Open access

Peer reviewed

K.S. Tewari, I. Vergote, A. Oaknin, E. Alvarez, S. Gaillard, S. Lheureux, D. Rischin, A.D. Santin, M. Feng, M. Mathias, …

Annals of oncology, Vol.29, pp.ix86-ix86

11/2018

PMID: 32178175

Files and links (1)

url

https://doi.org/10.1093/annonc/mdy436.027View

Published (Version of record) Open

1 Record Views

Title: GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer
Creators: K.S. Tewari - Orange
I. Vergote - Gynaecological Oncology, Leuven Cancer Institute, Leuven, Belgium;
A. Oaknin - Hebron University
E. Alvarez - UCSF Helen Diller Family Comprehensive Cancer Center
S. Gaillard - Johns Hopkins University
S. Lheureux - Princess Margaret Cancer Centre
D. Rischin - Peter MacCallum Cancer Centre
A.D. Santin - Yale University
M. Feng - Regeneron
M. Mathias - Regeneron
M. Fury - Regeneron
I. Lowy - Regeneron
B.J. Monk - University of Arizona
Publication Details: Annals of oncology, Vol.29, pp.ix86-ix86
Publisher: Elsevier Ltd
Identifiers: 991005969017102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article